Skip to main content
. 2020 Aug 5;13(2):941–947. doi: 10.1159/000509075

Fig. 3.

Fig. 3

Examples of just a few of the FGFR inhibitors that have already shown promise especially for FGFR fusions as opposed to mutations. The ones in green have already received US FDA approval for the disease types as shown. These drugs have variable degrees of potency and binding to various receptors/off-target effects. Resistance to one drug does not automatically exclude the use of others.